Enovix Corporation vs Erasca Inc. Common Stock — how do they compare? Enovix Corporation trades at $2.49 (market cap $549.72M), while Erasca Inc. Common Stock trades at $15.89 (market cap $5.40B). The key difference: Erasca Inc. Common Stock is far larger — about 9.8× Enovix Corporation's market cap, and Erasca Inc. Common Stock is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enovix Corporation for 11 Days and Erasca Inc. Common Stock for 0 Days on average.
| ENVX | ERAS | |
|---|---|---|
Market Cap | $549.72M | $5.40B |
Volume | 6,635,687 | 9,533,185 |
Sector | Industrials | Health |
52-Week High | $13.19 | $22.47 |
52-Week Low | $2.50 | $2.20 |
Typical Hold Time | 11 Days | 0 Days |
Enterprise Value | $611.42M | $5.18B |
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $2.485, down 2.55% on the day, reflecting a bearish technical outlook. The company continues to post significant losses, with a net income margin of -473.89% in 2026, though quarterly earnings have consistently beaten expectations. Recent news is dominated by a sudden CEO transition, but the company reaffirmed its strategy and guidance, highlighting progress in its drone and defense battery supply chain.
The outlook is highly speculative. Analyst consensus is bullish with a $10.75 price target, but substantial execution risks and persistent cash burn pose a threat to shareholder value. Investment potential hinges on successful commercialization and achieving profitability, which remains distant.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →Erasca is a biotechnology company developing precision medicines for cancer. Its programs target genetic drivers of tumor growth.
Read more on ERAS →